Avalon Advisors LLC Has Lifted Its Gilead Sciences Cmn (GILD) Position by $14.22 Million

December 14, 2017 - By Vivian Park

Investors sentiment increased to 0.93 in 2017 Q2. Its up 0.02, from 0.91 in 2017Q1. It increased, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Clearbridge Investments stated it has 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Selz Capital Limited Com, a New York-based fund reported 70,000 shares. Blair William And Il reported 1.51M shares stake. Advisor Prns Lc reported 21,633 shares. Texas Financial Bank Tx reported 0.56% stake. Waters Parkerson & Limited Liability owns 4,210 shares for 0.03% of their portfolio. Texas-based Afam Incorporated has invested 0.61% in Gilead Sciences, Inc. (NASDAQ:GILD). Commerzbank Aktiengesellschaft Fi holds 0.43% or 360,731 shares. Spirit Of America Management Ny accumulated 0.04% or 5,300 shares. Norinchukin Fincl Bank The invested in 0.27% or 182,827 shares. Amer Money Ltd Company stated it has 0.93% in Gilead Sciences, Inc. (NASDAQ:GILD). Roanoke Asset Mngmt New York stated it has 52,080 shares or 1.75% of all its holdings. Altavista Wealth Management stated it has 0.13% in Gilead Sciences, Inc. (NASDAQ:GILD). 177,500 were reported by Spark Invest Mngmt Ltd Co. 92,917 were accumulated by Tiverton Asset Ltd Liability Corp.

Since August 1, 2017, it had 0 buys, and 9 sales for $36.34 million activity. 73,333 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $6.09 million were sold by MARTIN JOHN C. The insider Alton Gregg H sold 25,000 shares worth $2.07M. 60,000 shares valued at $4.99M were sold by Meyers James R on Thursday, August 31.

Avalon Advisors Llc increased its stake in Gilead Sciences Cmn (GILD) by 214.65% based on its latest 2017Q2 regulatory filing with the SEC. Avalon Advisors Llc bought 203,112 shares as the company’s stock declined 8.05% while stock markets rallied. The hedge fund held 297,736 shares of the health care company at the end of 2017Q2, valued at $21.07 million, up from 94,624 at the end of the previous reported quarter. Avalon Advisors Llc who had been investing in Gilead Sciences Cmn for a number of months, seems to be bullish on the $100.03B market cap company. The stock increased 0.64% or $0.49 during the last trading session, reaching $76.58. About 9.97M shares traded or 20.92% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since December 14, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Avalon Advisors Llc, which manages about $4.06 billion and $3.01B US Long portfolio, decreased its stake in Verizon Communications Inc. Cm (NYSE:VZ) by 228,909 shares to 690,498 shares, valued at $30.84 million in 2017Q2, according to the filing. It also reduced its holding in Bristol (NYSE:BMY) by 160,290 shares in the quarter, leaving it with 18,962 shares, and cut its stake in Microsoft Corporation Cmn (NASDAQ:MSFT).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Finance.Yahoo.com which released: “Gilead Sciences to Acquire Cell Design Labs for $567 Million” on December 08, 2017, also Reuters.com with their article: “Gilead’s new drug keeps 56 percent of lymphoma trial patients alive” published on December 10, 2017, Seekingalpha.com published: “Gilead – Another Sobering Moment, But There Is More” on November 28, 2017. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences: Going Down When It Should Go Up” published on December 08, 2017 as well as Seekingalpha.com‘s news article titled: “Gilead Sciences – Brewing Stellar Molecule For NASH” with publication date: December 13, 2017.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.12’s average target is 26.82% above currents $76.58 stock price. Gilead Sciences had 107 analyst reports since July 29, 2015 according to SRatingsIntel. Morgan Stanley downgraded Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, October 2 to “Equal-Weight” rating. Leerink Swann downgraded Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, September 27 to “Mkt Perform” rating. The firm has “Outperform” rating by Leerink Swann given on Friday, February 5. The rating was initiated by Atlantic Securities on Friday, December 18 with “Neutral”. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, July 29. The company was downgraded on Monday, November 13 by Argus Research. Vetr upgraded the stock to “Buy” rating in Monday, August 17 report. The company was upgraded on Monday, January 18 by Bank of America. Cowen & Co maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, October 18. Cowen & Co has “Buy” rating and $90.0 target. Credit Suisse maintained the shares of GILD in report on Monday, August 28 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.